Can smartphones and wearables unlock the secrets of atrial fibrillation?

NCT ID NCT04404465

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study aims to better understand atrial fibrillation (AFib), the most common abnormal heart rhythm. Researchers will use mobile devices like ECG patches and a smartphone app to monitor heart rhythm, activity, and sleep in 3,000 adults, some with AFib and some without. Participants will also provide blood and saliva samples and undergo annual heart imaging for three years. The goal is to find markers that can predict who will develop AFib, whose condition will worsen, or who will respond best to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict who is at risk for atrial fibrillation and who will respond best to treatment.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test any new therapy. The findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Sep 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with a diagnosis of AF (i.e. new onset AF, paroxysmal AF, persistent AF, Permanent AF), those undergoing AF ablation or DCCV, those with a PAC greater or equal to 5% PAC burden, those undergoing SVT ablation, subjects with high risk of AF and healthy volunteers at least 18 years of age or older who have been seen at UCSF, who meet the inclusion and exclusion criteria will be eligible for participation in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At least 18 years of age or older 2. English speaking 3. Able to consent 4. ANY one of the following criteria: 1. Patients undergoing ablation for AF. 2. A history of non-valvular AF or AFL (not due to a reversible cause) documented on ECG or ambulatory monitoring within 1 year of enrollment and not on chronic anti-arrhythmic drugs (AAD). 3. A history of newly diagnosed persistent AF with documented normal sinus rhythm within 6 months of enrollment and undergoing cardioversion fot AF. 4. Two or more of the following criteria if no history of AF: * Age \> 65 years of age * A diagnosis of hypertension * A diagnosis of diabetes * A diagnosis of sleep apnea * A BMI ≥ 30 * Stable HF with preserved or reduced ejection fraction (NYHA Class I, II or III) * CKD not requiring dialysis 5. More than 5% PAC burden on ambulatory ECG monitoring (e.g. Holter, Ziopatch, Lifewatch, etc.) 6. Patients undergoing EP study or ablation for SVT with no history of AF and not meeting any of the above criteria (a-c). Exclusion Criteria: 1. Life expectancy \< 1 year 2. Reversible causes of AF (e.g., post-operative AF, cardiac surgery, pulmonary embolism, untreated hyperthyroidism) 3. Pregnant at the time of enrollment 4. Unwilling/unable to perform follow-up using digital follow-up 5. CKD requiring dialysis 6. Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data 7. Patients undergoing active treatment for cancer or diagnosed with cancer requiring treatment in the last 2 years 8. Severe Valvular Disease (eg. Rheumatic Heart Disease, Severe Mitral Valve Regurgitation, severe tricuspid regurgitation, severe aortic stenosis, or valve replacements) 9. History of organ transplant 10. History of any significant congenital heart defect 11. Existing Pacemakers and ICDs if not undergoing an ablation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.